Abstract
The clinical significance of neuron-specific enolase (NSE) as a tumour marker was evaluated in 54 patients with seminoma. Before orchiectomy NSE was elevated in six out of 21 patients with stage I seminoma and 11 out of 16 patients with metastases. After orchiectomy NSE normalised in all evaluated stage I cases, but was still elevated in six out of 12 patients with metastatic disease. NSE monitored the effect of cisplatin-based chemotherapy in patients with metastases. In some patients, increased serum NSE was found together with raised levels of human choriogonadotropin (HCG) and lactate dehydrogenase (LDH), while in others only NSE was elevated. No false positive NSE values were observed. NSE seems to be a clinically worthwhile serum tumour marker for monitoring seminoma patients, with a sensitivity and specificity of the same order as HCG.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Carney D. N., Marangos P. J., Ihde D. C., Bunn P. A., Jr, Cohen M. H., Minna J. D., Gazdar A. F. Serum neuron-specific enolase: a marker for disease extent and response to therapy of small-cell lung cancer. Lancet. 1982 Mar 13;1(8272):583–585. doi: 10.1016/s0140-6736(82)91748-2. [DOI] [PubMed] [Google Scholar]
- Fosså A., Fosså S. D. Serum lactate dehydrogenase and human choriogonadotrophin in seminoma. Br J Urol. 1989 Apr;63(4):408–415. doi: 10.1111/j.1464-410x.1989.tb05228.x. [DOI] [PubMed] [Google Scholar]
- Fosså S. D., Aass N., Kaalhus O. Testicular cancer in young Norwegians. J Surg Oncol. 1988 Sep;39(1):43–63. doi: 10.1002/jso.2930390110. [DOI] [PubMed] [Google Scholar]
- Fosså S. D., Langmark F., Aass N., Andersen A., Lothe R., Børresen A. L. Second non-germ cell malignancies after radiotherapy of testicular cancer with or without chemotherapy. Br J Cancer. 1990 Apr;61(4):639–643. doi: 10.1038/bjc.1990.142. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Heitz P. U. Neuroendocrine tumor markers. Curr Top Pathol. 1987;77:279–306. doi: 10.1007/978-3-642-71356-9_12. [DOI] [PubMed] [Google Scholar]
- Kuzmits R., Schernthaner G., Krisch K. Serum neuron-specific enolase. A marker for responses to therapy in seminoma. Cancer. 1987 Sep 1;60(5):1017–1021. doi: 10.1002/1097-0142(19870901)60:5<1017::aid-cncr2820600516>3.0.co;2-d. [DOI] [PubMed] [Google Scholar]
- Niehans G. A., Manivel J. C., Copland G. T., Scheithauer B. W., Wick M. R. Immunohistochemistry of germ cell and trophoblastic neoplasms. Cancer. 1988 Sep 15;62(6):1113–1123. doi: 10.1002/1097-0142(19880915)62:6<1113::aid-cncr2820620614>3.0.co;2-0. [DOI] [PubMed] [Google Scholar]
- Nielsen O. S., Munro A. J., Duncan W., Sturgeon J., Gospodarowicz M. K., Jewett M. A., Malkin A., Thomas G. M. Is placental alkaline phosphatase (PLAP) a useful marker for seminoma? Eur J Cancer. 1990;26(10):1049–1054. doi: 10.1016/0277-5379(90)90049-y. [DOI] [PubMed] [Google Scholar]
- Paus E., Fosså A., Fosså S. D., Nustad K. High frequency of incomplete human chorionic gonadotropin in patients with testicular seminoma. J Urol. 1988 Mar;139(3):542–544. doi: 10.1016/s0022-5347(17)42515-8. [DOI] [PubMed] [Google Scholar]
- Paus E., Nustad K. Immunoradiometric assay for alpha gamma- and gamma gamma-enolase (neuron-specific enolase), with use of monoclonal antibodies and magnetizable polymer particles. Clin Chem. 1989 Oct;35(10):2034–2038. [PubMed] [Google Scholar]
- Peckham M. J., McElwain T. J., Barrett A., Hendry W. F. Combined management of malignant teratoma of the testis. Lancet. 1979 Aug 11;2(8137):267–270. doi: 10.1016/s0140-6736(79)90288-5. [DOI] [PubMed] [Google Scholar]
- Takashi M., Haimoto H., Nagai T., Koshikawa T., Kato K. Enolase isozymes in seminoma. Urol Res. 1990;18(3):175–180. doi: 10.1007/BF00295843. [DOI] [PubMed] [Google Scholar]
- Wibe E., Paus E., Aamdal S. Neuron specific enolase (NSE) in serum of patients with malignant melanoma. Cancer Lett. 1990 Jun 30;52(1):29–31. doi: 10.1016/0304-3835(90)90073-7. [DOI] [PubMed] [Google Scholar]